InnovAtlasMalaria No More
Non-profit innovator

PATH

DiscoverDevelopDeliver

PATH works with national malaria programs and partners to develop, evaluate, introduce, and expand access to malaria vaccines, diagnostics, and other tools, and to strengthen surveillance and data systems.

7
Endemic countries
2
U.S. states
14
Products and programs
About

What they do

PATH works with national malaria programs and partners to develop, evaluate, introduce, and expand access to malaria vaccines, diagnostics, and other tools, and to strengthen surveillance and data systems.1 A development partner for the RTS,S/AS01 malaria vaccine, PATH now supports ministries of health in introducing both World Health Organization (WHO)-recommended malaria vaccines, RTS,S/AS01 and R21/Matrix-M, sponsors studies to optimize their deployment, and advances next-generation vaccine candidates and monoclonal antibodies.1 PATH also develops rapid diagnostic tests and reagents that improve malaria detection, including where HRP2/3 gene deletions affect existing tests, and G6PD tests that enable safer radical cure of P. vivax malaria.1 It also supports community and facility case management and chemoprevention, and develops repellent-treated fabrics.1 PATH is headquartered in Seattle, Washington, with laboratory and product-engineering capacity, and its malaria work spans the discovery, development, and delivery stages.1

In the United States
Products and programs

In the field and in development

RTS,S/AS01 post-introduction research2,1
RTS,S/AS01 and R21/Matrix-M introduction, optimization, and uptake support2,1
Clinical development of a novel prophylactic monoclonal antibody1
Pre-clinical and clinical development of novel vaccine candidates1
Malaria Control and Elimination Partnership in Africa (MACEPA)1
Novel repellent textiles for protection from disease vectors (Deployed Warfighter Protection Research Program)3,1
Reaching Every At-Risk Community and Household with Malaria Services (REACH Malaria)1
AFGHS–PATH1
Rotary Healthy Communities Challenge1
Sustainable and Integrated Data Systems1
PARADIGM diagnostics program1

WHO prequalification of the first tests recommended for regions with high rates of HRP2/3 deletions, with more WHO-prequalified tests expected within the next two quarters

G6PD testing1

Led to prequalification of the first G6PD test enabling radical cure of P. vivax

Second point-of-care G6PD test in prequalification1
Novel malaria biomarkers and reagents1

Collaboration with Monod Bio on LDH-binding reagents (NovoBodies) for next-generation malaria RDTs, including detection of infections with HRP2/3 gene deletions

Where they work

Partnerships in 7 endemic countries

Product testingPrograms and deliverySurveillance and genomicsClinical trialsResearch
Brazil
Latin America
  • Brazil's Ministry of Health and Medicines for Malaria Venture · generation and review of real-world evidence supporting the adoption and rollout of single-dose tafenoquine with quantitative G6PD testing for P. vivax malaria1
  • Malaria RDT clinical evaluation sites, through Burnet Australia1
  • Malaria vaccine development and optimization: PATH serves as sponsor for clinical studies designed to establish proof-of-concept for a novel vaccine and optimization of deployment of current vaccines (Burkina Faso) with partners in Africa1
Ethiopia
Africa
  • Malaria RDT clinical evaluation sites, through Burnet Australia1
Lao PDR
Asia-Pacific
  • Malaria RDT clinical evaluation sites, through Burnet Australia1
Malawi
Africa
  • Malaria RDT clinical evaluation sites, through Burnet Australia1
Papua New Guinea
Asia-Pacific
  • Malaria RDT clinical evaluation sites, through Burnet Australia1
Zambia
Africa
  • Ministry of Health and National Malaria Elimination Centre · surveillance, data use, community and facility case management, and malaria-control activities through MACEPA, REACH Malaria, the Rotary Healthy Communities Challenge, and the Sustainable and Integrated Data Systems project1
Across several countries
  • Malaria vaccine introduction — technical assistance to national ministries of health and country partners supporting the rollout and uptake of RTS,S/AS01 and R21/Matrix-M in African countries1
U.S. partners

Who they work with in the United States

  • Anovotek LLC3,1
    Barnwell, SC · commercial and technical partner for repellent-treated fabrics
    In the atlas
  • U.S. Department of Defense Deployed Warfighter Protection Program1
    support for repellent-treated fabric research
    In the atlas
  • U.S. Department of State1
    Funder · funder of REACH Malaria and AFGHS–PATH
  • Stanford University1
    Stanford, CA
    In the atlas
  • Duke University1
    Durham, NC
    In the atlas
  • Fred Hutchinson Cancer Center1
    Seattle, WA · research partners, with Gates Foundation partners, using clinical samples from a PATH-sponsored trial to identify the biological basis and biomarkers of vaccine efficacy and inform next-generation vaccines
    In the atlas
  • Monod Bio1
    research and technology development partner developing and evaluating novel parasite lactate dehydrogenase-binding reagents for next-generation malaria rapid diagnostic tests
    In the atlas
Sources

Where this comes from

  1. 1Confirmed by the organization
  2. 2path.org
  3. 3bvec.nd.edu